ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Atlas-Guided CD55-Enriched Neutrophil Extracellular Vesicles for Complement-Macrophage Modulation in Diabetic Wounds.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds are characterized by persistent inflammation and impaired immune resolution, yet the therapeutic translation of single-cell atlases into rational immunomodulatory strategies remains limited. Here, integration of diabetic-wound single-cell transcriptomic datasets identifies a neutrophil subpopulation enriched in cluster of differentiation 55 (CD55) with complement-regulatory and reparative features. Guided by this atlas-derived signature, activated neutrophil-derived extracellular vesicles (aNEVs) enriched in CD55 are generated under high-glucose and lipopolysaccharide stimulation and incorporated into a microbial transglutaminase-crosslinked gelatin hydrogel for localized delivery and protease-sensitive matrix remodeling. The resulting gelatin/aNEV composite hydrogel (Gel/aNEV) attenuates complement-associated inflammatory signaling, C3a production, oxidative stress, and pro-inflammatory cytokine expression, while promoting reparative macrophage reprogramming and endothelial migration. In diabetic wounds, a single application of Gel/aNEV accelerates wound closure and enhances angiogenesis, collagen remodeling, and tissue regeneration. Integrated transcriptomic-proteomic analyses further reveal coordinated changes in complement, inflammatory, redox, extracellular-matrix, and regenerative programs, supporting a multicomponent therapeutic model. Collectively, this study establishes an atlas-to-therapy framework that uses disease-associated neutrophil states to guide extracellular-vesicle engineering, integrating complement regulation, immune reprogramming, and biomaterial-assisted delivery for diabetic wound repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.